Harriet Richardson, BSc, MSc, PhD
- Investigator, CCTG and CCE divisions
- 2nd Floor, Queen's Cancer Research Institute
- Kingston, Ontario
- K7L 3N6
- Telephone: 613-533-6000 x78958
- E-Mail: firstname.lastname@example.org
- Member, Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen's University
- Associate Professor, Department of Public Health Sciences
- Cross Appointment with Canadian Cancer Trials Group (CCTG) as Project Coordinator
Dr. Richardson is an epidemiologist and professor in the Department of Public Health Sciences at Queen's University. Dr. Richardson, who bridges the Canadian Cancer Trials Group (CCTG) and the Division of Cancer Care and Epidemiology, has focussed on breast cancer prevention in the context of clinical trials (e.g. evaluating anti-estrogen agents and their effect on breast cancer incidence and/or mammographic density). She is the senior author of a ground-breaking paper published in the New England Journal of Medicine in June 2011 relating to Exemestane for breast cancer prevention in postmenopausal women. Additional studies evaluate how aromatase inhibitors affect bone strength and quality. Her research also involves tissue and blood banking for future biomarker development projects, evaluating quality of life data from clinical trials, and evaluating family physician knowledge and practice patterns in breast cancer prevention.
- Cancer prevention trial methodology
- Describing (for the purpose of improving) family physicians' use of primary prevention strategies
- Quality of life data from clinical trials
Dr. Richardson's publications are available on PubMed.
Last Modified: 2017-08-03